Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,199.8
26.9 (0.85%)

 

  • STI Straits Times Index
    3,199.8
    26.9 (0.85%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,570.3
    7.1 (0.45%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,981.1
    335.7 (1.26%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,920.1
    -4.3 (-0.15%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,441.8
    49.9 (0.21%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,191.2
    11.1 (0.18%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,131.8
    26.1 (1.24%)
    Index delayed 20 minutes
  • XAO XAO
    6,806.4
    -46.8 (-0.68%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 248.7M
  • Value: 353.5M
  • Rise: 113
  • Fall: 80
  • Unch: 633

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.173+0.006
Tritech0.025+0.002
Golden Agri-Res0.220-0.005
Mapletree NAC Tr1.140-0.020
Dyna-Mac0.126+0.006
YZJ Shipbldg SGD1.100+0.020
Suntec Reit1.820-0.010
Mapletree Com Tr2.310-0.020
GSS Energy0.081+0.003
Broadway Ind^0.065+0.003

World Indices

World Indices
Name Last Change
Nasdaq 8,654.1 +37.9
HSI 26,949.4 +304.0
HSCEI 10,618.7 +116.1
Jakarta 6,194.1 +14.0
Nikkei 225 23,444.3 +52.5
SSE Comp 2,917.4 -7.0
Shanghai A 3,057.0 -7.3
Shanghai B 242.7 -1.5
PSE Comp 0.0
KOSPI 2,132.2 +26.5

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

BEIGENE BEIGENE
Quotes 15 Minutes Delayed. Updated at 12 Dec 2019 10:23
Last (HKD): 108.300 Change: -2.000 High: 109.000 Remarks: -
Change (%): -1.81 Low: 107.400
Open 107.900 Yesterday's Close 110.300
Buy Price 108.400 Sell Price 109.200
Buy Volume ('000) 0.2 Sell Volume ('000) 0.5
Cumulative Volume ('000) 10.3 Cumulative Value 1,115,700
 
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a -6.65126 Trailing EPS (HKD) e -8.17802 NAV (HKD) b 12.6238
PE a - Trailing PE f - Price / NAV b 8.5790
Dividend (HKD) d - Cash In Hand (HKD) g 8.5946 Issued & Paid-up Shares c 793,939,000
Dividend Yield (%) d - Price / Cash In Hand g 12.601 Treasury Shares h -
Beta - 75 Daysi 0.737 R-Squared - 75 Days(%)i 2.27 Market Cap (M) 85,983.594
Beta - 500 Daysi 1.147 R-Squared - 500 Days (%)i 13.78 Enterprise Value (M) 78,573.621
Piotroski F Score 2 Exchange Code 6160 Par Value ( USD ) 0.00010
52 Weeks Volatility (%) 48.30 6-Month VWAP 98.160 Free Float (%) 88.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 03 Dec 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 02 Aug 2018.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference BEIGENE HKEx 85,983.594 - - 8.5790 -
Industry Biotechnology HKEx 47,663.213 14.027 14.981 5.9708 2.605
Local Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Local Peer SINO BIOPHARM HKEx 128,811.093 12.022 12.477 3.8361 0.714
Local Peer WUXI BIO HKEx 118,940.862 159.245 124.493 12.2434 -
Local Peer GENSCRIPT BIO HKEx 35,198.229 211.672 - 9.9258 -
Local Peer 3SBIO HKEx 26,669.685 17.630 21.458 2.6286 -
Local Peer HAOHAI BIOTEC HKEx 13,224.331 26.933 29.850 3.1136 0.786
Local Peer FRONTAGE HKEx 8,351.782 94.804 94.797 4.3225 -
Local Peer CKLIFE SCIENCES HKEx 7,784.967 29.605 29.564 1.8646 1.235
Local Peer VIVA BIOTECH HKEx 6,701.405 62.482 62.483 3.4791 -
Local Peer ASCENTAGE-B HKEx 6,278.686 - - -3.4000 -
Local Peer SINOMAB BIO-B HKEx 4,055.147 - - - -
Local Peer ASCLETIS-B HKEx 3,731.898 - - 0.9682 -
Other Local Peers ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), BBI LIFE SCI (HKEx), UNI-BIO GROUP (HKEx), CT ENTERPRISE (HKEx), BIOSINO BIO-TEC (HKEx), REGENT PACIFIC (HKEx), EXTRAWELL PHAR (HKEx), HAO WEN HLDGS (HKEx)
Global Peer AMGEN INC NASDAQ 139,044.998 16.565 17.236 12.7249 2.391
Global Peer CSL ASX 128,058.856 47.731 47.731 17.1130 0.940
Global Peer GILEAD SCIENCES INC NASDAQ 85,751.867 15.720 31.843 4.1619 3.409
Global Peer VERTEX PHARMACEUTICAL NASDAQ 56,573.000 26.986 26.390 10.7688 -
Global Peer BIOGEN INC NASDAQ 52,730.566 11.901 9.773 3.7676 -
Global Peer ILLUMINA INC NASDAQ 47,123.790 57.051 48.431 10.6158 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 41,012.089 16.778 19.127 3.9043 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 25,815.821 81.695 24.104 5.4372 0.734
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,231.364 312.259 16.481 2.3373 -
Global Peer INCYTE CORPORATION NASDAQ 20,447.637 186.749 50.492 8.4406 -
Other Global Peers SEATTLE GENETICS INC (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), Lonza (SGX), IMMUNOMEDICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), NATERA INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), UNIQURE N.V. (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), SYNTHORX INC (NASDAQ), INSMED INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), REGENXBIO INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), FATE THERAPEUTICS (NASDAQ), NEXTCURE INC (NASDAQ), VIELA BIO INC (NASDAQ), VERACYTE INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), TG THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), INTREXON CORP (NASDAQ), CORTEXYME INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), POLYNOVO LIMITED (ASX), MEIRAGTX HOLDINGS PLC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), XBIOTECH INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), KADMON HLDGS INC (NYSE), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), UROGEN PHARMA LTD (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), OMEROS CORP (NASDAQ), MESOBLAST LTD (ASX), INTRA-CELLUAR THERAPIES INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), AVROBIO INC (NASDAQ), RETROPHIN INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), IMMUNOGEN INC (NASDAQ), CYTOKINETICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), AGENUS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MERUS B V (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), MACROGENICS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), RECRO PHARMA INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), AVID BIOSERVICES INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), MEDICINOVA INC (NASDAQ), COMPUGEN (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), KAMADA (NASDAQ), PERSONALIS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), ELOXX PHARMACEUTICALS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), MANNKIND CORPORATION (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), PFENEX INC (NYSE American), ADMA BIOLOGICS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), NEXT SCIENCE LTD (ASX), DPHARMA (Bursa), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), CHIASMA INC (NASDAQ), IVERIC BIO INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), XOMA CORP (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ATHERSYS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ARAVIVE INC (NASDAQ), AFFIMED N V (NASDAQ), NANTKWEST INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), GALECTIN THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), IMV INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), NANOVIRICIDES INC (NYSE American), ENZO BIOCHEM INC (NYSE), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CHIMERIX INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), FENNEC PHARMACEUTICALS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SESEN BIO INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), NOVAVAX INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), PARATEK PHARMACEUTICALS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), IMUGENE LIMITED (ASX), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ADURO BIOTECH INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), VTV THERAPEUTICS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), SYNLOGIC INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), INFLARX N V (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), EQUILLIUM INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VERMILLION INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), CEL-SCI CORP (NYSE American), ITERUM THERAPEUTICS PLC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), TREVENA INC (NASDAQ), IMMUTEP LTD (ASX), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), SURFACE ONCOLOGY INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), CURIS INC (NASDAQ), INMUNE BIO INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ORTHOCELL LIMITED (ASX), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), SAVARA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), RESTORBIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ORGENESIS INC (NASDAQ), PORT (SET), ARMATA PHARMACEUTICALS INC (NYSE American), BELLICUM PHARMACEUTICALS (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ISORAY INC (NYSE American), DIAMEDICA THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), BIONOMICS LTD (ASX), EVOGENE LTD (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), NEON THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ZAFGEN INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), FIBROCELL SCIENCE INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), BIOCARDIA INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), ORAGENICS INC (NYSE American), VISTAGEN THERAPEUTICS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), MEMPHASYS LTD (ASX), SOLIGENIX INC (NASDAQ), BIOTRON (ASX), IBIO INC (NYSE American), RHINOMED LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ANTEOTECH LIMITED (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), REGENEUS LTD (ASX), PATRYS LIMITED (ASX), ATYR PHARMA INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SENESTECH INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), IMMURON LIMITED (ASX), DARE BIOSCIENCE INC (NASDAQ), CELLMID LIMITED (ASX), ADVAXIS INC (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), TOCAGEN INC (NASDAQ), PRECIPIO INC (NASDAQ), OCUGEN INC (NASDAQ), Suntar Eco-City^ (SGX), ALTERITY THERAPEUTICS LIMITED (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ADALTA LTD (ASX), CCP TECHNOLOGIES LTD (ASX), TROVAGENE INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), TRACON PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), MEGASUN (Bursa), AUSTRALIAN PRIMARY HEMP LTD (ASX), PLUS THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), MGRC (Bursa), ACHIEVE LIFE SCIENCE INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), MEDIBIO LIMITED (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), TBG DIAGNOSTICS LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), BIOXYNE LIMITED (ASX), BIOCEPT INC (NASDAQ), OPGEN INC (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), SPHERIX INC (NASDAQ), QT Vascular (SGX), AURIS MEDICAL HOLDING LTD (NASDAQ), BPH ENERGY LIMITED (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --11.700
-9.75 %
10 Days --12.500
-10.35 %
20 Days --7.800
-6.72 %
Medium Term Return 3 Months -+31.600
+41.20 %
6 Months -+32.500
+42.88 %
1 Year -+26.500
+32.40 %
Annualised Return Annualised --
+32.40 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 69.500 - 132.000 Change From 1 Year Low +38.800 % Change From 1 Year Low (%) +55.83
Change From 1 Year High -23.700 % Change From 1 Year High (%) -17.95
2 Years Range 61.050 - 132.000 Change From 2 Years Low +47.250 % Change From 2 Years Low (%) +77.40
Change From 2 Years High -23.700 % Change From 2 Years High (%) -17.95
5 Years Range 61.050 - 132.000 Change From 5 Years Low +47.250 % Change From 5 Years Low (%) +77.40
Change From 5 Years High -23.700 % Change From 5 Years High (%) -17.95
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Historical Price Data

Date Open High Low Close Volume VWAP
11 Dec 2019 110.600 111.400 110.000 110.300 101,100 110.7744
10 Dec 2019 111.500 111.500 109.000 111.000 98,301 110.7324
09 Dec 2019 114.000 114.000 111.400 112.100 27,700 111.9625
06 Dec 2019 114.200 115.500 113.400 114.800 57,200 114.3245
05 Dec 2019 117.400 118.000 113.900 115.800 45,500 116.0435
04 Dec 2019 119.300 120.000 119.000 120.000 45,300 119.2934
03 Dec 2019 120.700 121.500 120.100 120.700 52,100 120.7628
02 Dec 2019 121.900 122.200 120.900 120.900 50,500 121.3735
29 Nov 2019 121.000 121.300 118.100 120.200 66,000 119.5164
28 Nov 2019 120.800 121.600 119.700 120.200 62,200 120.5682
27 Nov 2019 124.500 124.500 118.400 120.800 53,500 121.0536
26 Nov 2019 126.300 126.300 124.200 124.900 103,300 125.0665
25 Nov 2019 124.500 128.700 124.300 126.300 80,500 126.3207
22 Nov 2019 124.000 124.000 121.400 123.400 751,000 121.8266
21 Nov 2019 120.500 120.900 120.000 120.400 61,600 120.3990
20 Nov 2019 121.500 123.000 120.300 121.000 122,400 121.3016
19 Nov 2019 117.000 121.300 113.500 119.200 249,700 118.8377
18 Nov 2019 120.600 123.900 120.300 121.500 344,500 121.7351
15 Nov 2019 120.100 132.000 120.100 125.200 647,100 124.7374
14 Nov 2019 117.000 118.000 116.000 117.400 91,100 116.9807
13 Nov 2019 117.000 119.500 114.300 116.100 74,100 116.9752
12 Nov 2019 114.600 116.900 114.200 114.700 37,400 115.6586
Summary
Current 2 Weeks
(28 Nov 2019 to 11 Dec 2019)		 120.800 122.200 109.000 110.300 605,901 -
Previous 2 Weeks
(14 Nov 2019 to 27 Nov 2019)		 117.000 122.200 109.000 120.800 2,504,700 -
4 Weeks from
(17 Oct 2019 to 13 Nov 2019)		 75.000 122.200 75.000 116.100 2,806,480 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.